Top

Open Access 25-04-2024 | Hemophilia

The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease

Authors: Ahmed E. Ali, Richard C. Becker

Published in: Journal of Thrombosis and Thrombolysis

Abstract

Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial fibrillation are the most common. In addition to their proclivity for thrombosis, each of these four conditions is also characterized by local and systemic inflammation, endothelial/endocardial injury and dysfunction, oxidative stress, impaired tissue-level reparative capabilities, and immune dysregulation that plays a critical role in linking molecular events, environmental triggers, and phenotypic expressions. Knowing that cardiovascular disease and thrombosis are complex and dynamic, can the scientific community identify a common pathway or specific point of interface susceptible to pharmacological inhibition or alteration that is likely to be safe and effective? The contact factors of coagulation may represent the proverbial “sweet spot” and are worthy of investigation. The following review provides a summary of the fundamental biochemistry of factor XI, its biological activity in thrombosis, inflammation, and angiogenesis, new targeting drugs, and a pragmatic approach to managing hemostatic requirements in clinical trials and possibly day-to-day patient care in the future.

Gailani D, Broze GJ Jr (1991) Factor XI activation in a revised model of blood coagulation. Science 253(5022):909–912. https://doi.org/10.1126/science.1652157CrossRefPubMed

Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renné T, Gruber A, Gailani D (2010) A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116(19):3981–3989. https://doi.org/10.1182/blood-2010-02-270918CrossRefPubMedPubMedCentral

Bouma BN, Griffin JH (1977) Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252(18):6432–6437CrossRefPubMed

McMullen BA, Fujikawa K, Davie EW (1991) Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 30(8):2056–2060. https://doi.org/10.1021/bi00222a008CrossRefPubMed

Walsh PN, Sinha D, Koshy A, Seaman FS, Bradford H (1986) Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. Blood 68(1):225–230CrossRefPubMed

Doolittle RF (2009) Step-by-step evolution of vertebrate blood coagulation. Cold Spring Harb Symp Quant Biol 74:35–40. https://doi.org/10.1101/sqb.2009.74.001CrossRefPubMed

Podmore A, Smith M, Savidge G, Alhaq A (2004) Real-time quantitative PCR analysis of factor XI mRNA variants in human platelets. J Thromb Haemost 2(10):1713–1719. https://doi.org/10.1111/j.1538-7836.2004.00924.xCrossRefPubMed

Zhang X, Lewandowska M, Aldridge M, Iglay K, Wolford E, Shapiro A (2023) Global epidemiology of factor XI deficiency: a targeted review of the literature and foundation reports. Haemophilia 29(2):423–434. https://doi.org/10.1111/hae.14687CrossRefPubMed

Maas C, Renné T (2018) Coagulation factor XII in thrombosis and inflammation. Blood 131(17):1903–1909. https://doi.org/10.1182/blood-2017-04-569111CrossRefPubMed

10.

Gruber A, Hanson SR (2003) Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 102(3):953–955. https://doi.org/10.1182/blood-2003-01-0324CrossRefPubMed

11.

Puy C, Tucker EI, Matafonov A, Cheng Q, Zientek KD, Gailani D, Gruber A, McCarty OJ (2015) Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood 125(9):1488–1496. https://doi.org/10.1182/blood-2014-10-604587CrossRefPubMedPubMedCentral

12.

Baglia FA, Badellino KO, Li CQ, López JA, Walsh PN (2007) Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem 282(39):29067. https://doi.org/10.1016/s0021-9258(20)58639-0CrossRefPubMed

13.

Nieuwland R, Gardiner C, Dignat-George F, Mullier F, Mackman N, Woodhams B, Thaler J (2019) Toward standardization of assays measuring extracellular vesicle-associated tissue factor activity. J Thromb Haemost 17(8):1261–1264. https://doi.org/10.1111/jth.14481CrossRefPubMedPubMedCentral

14.

Greengard JS, Heeb MJ, Ersdal E, Walsh PN, Griffin JH (1986) Binding of coagulation factor XI to washed human platelets. Biochemistry 25(13):3884–3890. https://doi.org/10.1021/bi00361a022CrossRefPubMed

15.

Miller TN, Sinha D, Baird TR, Walsh PN (2007) A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets. Biochemistry 46(50):14450–14460. https://doi.org/10.1021/bi701310xCrossRefPubMed

16.

Fogelson AL, Hussain YH, Leiderman K (2012) Blood clot formation under flow: the importance of factor XI depends strongly on platelet count. Biophys J 102(1):10–18. https://doi.org/10.1016/j.bpj.2011.10.048CrossRefPubMedPubMedCentral

17.

Humphreys SJ, Whyte CS, Mutch NJ (2023) “Super” SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions. Front Cardiovasc Med 10:1146833. https://doi.org/10.3389/fcvm.2023.1146833CrossRefPubMedPubMedCentral

18.

Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134(5):1087–1097PubMedPubMedCentral

19.

Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24(6):1015–1022. https://doi.org/10.1161/01.Atv.0000130465.23430.74CrossRefPubMed

20.

Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U, Koyama T, Niepmann M, Trusheim H, Engelmann B, Preissner KT (2005) Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). Biochem J 385(Pt 3):831–838. https://doi.org/10.1042/bj20041021CrossRefPubMedPubMedCentral

21.

Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Günther A, Engelmann B, Preissner KT (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104(15):6388-6393.https://doi.org/10.1073/pnas.0608647104

22.

Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D (2009) Factor XI contributes to thrombin generation in the absence of factor XII. Blood 114(2):452–458. https://doi.org/10.1182/blood-2009-02-203604CrossRefPubMedPubMedCentral

23.

Choi SH, Smith SA, Morrissey JH (2011) Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 118(26):6963–6970. https://doi.org/10.1182/blood-2011-07-368811CrossRefPubMedPubMedCentral

24.

Pike GN, Cumming AM, Hay CR, Bolton-Maggs PH, Burthem J (2015) Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency. Blood 126(3):397–405. https://doi.org/10.1182/blood-2014-12-616565CrossRefPubMed

25.

Staritz P, de Moerloose P, Schutgens R, Dolan G (2013) Applicability of the European society of cardiology guidelines on management of acute coronary syndromes to people with haemophilia - an assessment by the ADVANCE working group. Haemophilia 19(6):833–840. https://doi.org/10.1111/hae.12189CrossRefPubMed

26.

Zucker M, Seligsohn U, Salomon O, Wolberg AS (2014) Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost 12(7):1121–1130. https://doi.org/10.1111/jth.12600CrossRefPubMedPubMedCentral

27.

Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP (2001) Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86(4):959–972PubMed

28.

Maroney SA, Mast AE (2008) Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci 38(1):9–14. https://doi.org/10.1016/j.transci.2007.12.001CrossRefPubMedPubMedCentral

29.

Becker RC, Alexander JH, Li Y, Robertson T, Kunitada S, Spencer FA, Yang H, Harrington RA (2004) Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a–a selective and direct factor Xa inhibitor. J Thromb Thrombolysis 18(3):193–197. https://doi.org/10.1007/s11239-005-0345-6CrossRefPubMed

30.

Ameri A, Kuppuswamy MN, Basu S, Bajaj SP (1992) Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79(12):3219–3226CrossRefPubMed

31.

Crawley JT, Lane DA (2008) The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28(2):233–242. https://doi.org/10.1161/atvbaha.107.141606CrossRefPubMed

32.

Becker RC, Mahaffey KW, Yang H, Marian AJ, Furman MI, Michael Lincoff A, Hazen SL, Petersen JL, Reist CJ, Kleiman NS (2011) Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis 31(2):146–153. https://doi.org/10.1007/s11239-010-0532-yCrossRefPubMed

33.

Reitsma SE, Holle LA, Bouck EG, Monroe DM, Mast AE, Burthem J, Bolton-Maggs PHB, Gidley GN, Wolberg AS (2023) Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency. J Thromb Haemost 21(3):467–479. https://doi.org/10.1016/j.jtha.2022.10.005CrossRefPubMed

34.

Puy C, Rigg RA, McCarty OJ (2016) The hemostatic role of factor XI. Thromb Res 141 Suppl 2(Suppl 2):S8-s11. https://doi.org/10.1016/s0049-3848(16)30354-1CrossRefPubMed

35.

MacDonald S, White D, Langdown J, Downes K, Thomas W (2020) Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity. Int J Lab Hematol 42(3):246–255. https://doi.org/10.1111/ijlh.13155CrossRefPubMed

36.

Chelle P, Montmartin A, Damien P, Piot M, Cournil M, Lienhart A, Genre-Volot F, Chambost H, Morin C, Tardy-Poncet B (2019) Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients. Haemophilia 25(2):343–348. https://doi.org/10.1111/hae.13679CrossRefPubMed

37.

Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyák K, Ten Cate H, Rosing J (2008) Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 6(1):125–131. https://doi.org/10.1111/j.1538-7836.2007.02824.xCrossRefPubMed

38.

Mast AE (2016) Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol 36(1):9–14. https://doi.org/10.1161/atvbaha.115.305996CrossRefPubMed

39.

Patel-Hett S, Martin EJ, Mohammed BM, Rakhe S, Sun P, Barrett JC, Nolte ME, Kuhn J, Pittman DD, Murphy JE, Brophy DF (2019) Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia 25(5):797–806. https://doi.org/10.1111/hae.13820CrossRefPubMed

40.

Peterson JA, Maroney SA, Mast AE (2016) Targeting TFPI for hemophilia treatment. Thromb Res 141 Suppl 2(Suppl 2):S28-30. https://doi.org/10.1016/s0049-3848(16)30359-0CrossRefPubMed

41.

Visser M, Heitmeier S, Ten Cate H, Spronk HMH (2020) Role of factor xia and plasma Kallikrein in arterial and venous thrombosis. Thromb Haemost 120(6):883–993. https://doi.org/10.1055/s-0040-1710013CrossRefPubMed

42.

Hugli TE, Müller-Eberhard HJ (1978) Anaphylatoxins: C3a and C5a. Adv Immunol 26:1–53. https://doi.org/10.1016/s0065-2776(08)60228-xCrossRefPubMed

43.

Sainz IM, Pixley RA, Colman RW (2007) Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 98(1):77–83CrossRefPubMed

44.

Pallares Robles A, Ten Cate V, Schulz A, Prochaska JH, Rapp S, Koeck T, Panova-Noeva M, Heitmeier S, Schwers S, Leineweber K, Seyfarth HJ, Opitz CF, Spronk H, Espinola-Klein C, Lackner KJ, Münzel T, Andrade-Navarro MA, Konstantinides SV, Ten Cate H, Wild PS (2022) Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Sci Rep 12(1):9761. https://doi.org/10.1038/s41598-022-13174-5CrossRefPubMedPubMedCentral

45.

Tucker EI, Verbout NG, Leung PY, Hurst S, McCarty OJ, Gailani D, Gruber A (2012) Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood 119(20):4762–4768. https://doi.org/10.1182/blood-2011-10-386185CrossRefPubMedPubMedCentral

46.

Møller S, Bernardi M (2013) Interactions of the heart and the liver. Eur Heart J 34(36):2804–2811. https://doi.org/10.1093/eurheartj/eht246CrossRefPubMed

47.

Cao Y, Wang Y, Zhou Z, Pan C, Jiang L, Zhou Z, Meng Y, Charugundla S, Li T, Allayee H, Seldin MM, Lusis AJ (2022) Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure. Science 377(6613):1399–1406. https://doi.org/10.1126/science.abn0910CrossRefPubMedPubMedCentral

48.

Jordan KR, Wyatt CR, Fallon ME, Woltjer R, Neuwelt EA, Cheng Q, Gailani D, Lorentz C, Tucker EI, McCarty OJT, Hinds MT, Nguyen KP (2022) Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis. J Thromb Haemost 20(9):2035–2045. https://doi.org/10.1111/jth.15777CrossRefPubMedPubMedCentral

49.

Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U (2008) Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111(8):4113–4117. https://doi.org/10.1182/blood-2007-10-120139CrossRefPubMed

50.

Sharman Moser S, Chodick G, Ni YG, Chalothorn D, Wang MD, Shuldiner AR, Morton L, Salomon O, Jalbert JJ (2022) The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events. Thromb Haemost 122(5):808–817. https://doi.org/10.1055/s-0041-1735971CrossRefPubMed

51.

Ngo ATP, Jordan KR, Mueller PA, Hagen MW, Reitsma SE, Puy C, Revenko AS, Lorentz CU, Tucker EI, Cheng Q, Hinds MT, Fazio S, Monia BP, Gailani D, Gruber A, Tavori H, McCarty OJT (2021) Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. J Thromb Haemost 19(4):1001–1017. https://doi.org/10.1111/jth.15236CrossRefPubMedPubMedCentral

52.

Shnerb Ganor R, Harats D, Schiby G, Gailani D, Levkovitz H, Avivi C, Tamarin I, Shaish A, Salomon O (2016) Factor XI deficiency protects against atherogenesis in apolipoprotein e/factor XI double knockout mice. Arterioscler Thromb Vasc Biol 36(3):475–481. https://doi.org/10.1161/atvbaha.115.306954CrossRefPubMed

53.

Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, Seiffert DA (2006) Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 4(9):1982–1988. https://doi.org/10.1111/j.1538-7836.2006.02093.xCrossRefPubMed

54.

Renné T, Oschatz C, Seifert S, Müller F, Antovic J, Karlman M, Benz PM (2009) Factor XI deficiency in animal models. J Thromb Haemost 7(Suppl 1):79–83. https://doi.org/10.1111/j.1538-7836.2009.03393.xCrossRefPubMed

55.

Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, Wang Y, Geary RS, Weitz J, Bhanot S (2022) Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(Rx) in patients with ESRD. Kidney Int Rep 7(2):200–209. https://doi.org/10.1016/j.ekir.2021.11.011CrossRefPubMed

56.

Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AWA, Bethune C, Morgan E, Yu RZ, Wang Y, Jung SW, Geary R, Bhanot S (2021) PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst Pharmacol 10(8):890–901. https://doi.org/10.1002/psp4.12663CrossRefPubMedPubMedCentral

57.

Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE (2020) Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 323(2):130–139. https://doi.org/10.1001/jama.2019.20687CrossRefPubMedPubMedCentral

58.

Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, Raskob GE, Weitz JI (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385(7):609–617. https://doi.org/10.1056/NEJMoa2105872CrossRefPubMed

59.

Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A (2021) The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood 138(22):2173–2184. https://doi.org/10.1182/blood.2021011725CrossRefPubMedPubMedCentral

60.

Nowotny B, Thomas D, Schwers S, Wiegmann S, Prange W, Yassen A, Boxnick S (2022) First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men. J Thromb Haemost 20(7):1684–1695. https://doi.org/10.1111/jth.15744CrossRefPubMedPubMedCentral

61.

Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJ, Gailani D, Gruber A, Hanson SR (2009) Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 113(4):936–944. https://doi.org/10.1182/blood-2008-06-163675CrossRefPubMedPubMedCentral

62.

Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE (2021) Milvexian for the prevention of venous thromboembolism. N Engl J Med 385(23):2161–2172. https://doi.org/10.1056/NEJMoa2113194CrossRefPubMedPubMedCentral

63.

Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, ... Hart RG (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 400(10357):997–1007. https://doi.org/10.1016/s0140-6736(22)01588-4

64.

Beale D, Dennison J, Boyce M, Mazzo F, Honda N, Smith P, Bruce M (2021) ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study. Br J Clin Pharmacol 87(8):3177–3189. https://doi.org/10.1111/bcp.14732CrossRefPubMed

65.

Chen R, Guan X, Hu P, Dong Y, Zhu Y, Zhang T, Zou J, Zhang S (2022) First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of SHR2285, a small-molecule factor XIa inhibitor in healthy subjects. Front Pharmacol 13:821363. https://doi.org/10.3389/fphar.2022.821363CrossRefPubMedPubMedCentral

66.

Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X, Knabb RM, Seiffert D, DeSouza M, Mugnier P, Cirincione B, Ueno T, Frost RJA (2018) First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol 84(5):876–887. https://doi.org/10.1111/bcp.13520CrossRefPubMedPubMedCentral

67.

Pollack CV Jr, Kurz MA, Hayward NJ (2020) EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report. Crit Care Explor 2(9):e0196. https://doi.org/10.1097/cce.0000000000000196CrossRefPubMedPubMedCentral

68.

Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR (2013) Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem 56(3):867–878. https://doi.org/10.1021/jm301338qCrossRefPubMedPubMedCentral

69.

Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, Frère JM, Feron O, Dogné JM, Dessy C, Vanhamme L, Godfroid E (2009) Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 206(11):2381–2395. https://doi.org/10.1084/jem.20091007CrossRefPubMedPubMedCentral

70.

Chen W, Carvalho LP, Chan MY, Kini RM, Kang TS (2015) Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost 13(2):248–261. https://doi.org/10.1111/jth.12797CrossRefPubMed

71.

Assumpção TC, Ma D, Mizurini DM, Kini RM, Ribeiro JM, Kotsyfakis M, Monteiro RQ, Francischetti IM (2016) In vitro mode of action and anti-thrombotic activity of boophilin, a multifunctional kunitz protease inhibitor from the midgut of a tick vector of babesiosis, rhipicephalus microplus. PLoS Negl Trop Dis 10(1):e0004298. https://doi.org/10.1371/journal.pntd.0004298CrossRefPubMedPubMedCentral

72.

Ma D, Mizurini DM, Assumpção TC, Li Y, Qi Y, Kotsyfakis M, Ribeiro JM, Monteiro RQ, Francischetti IM (2013) Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo. Blood 122(25):4094–4106. https://doi.org/10.1182/blood-2013-08-517474CrossRefPubMedPubMedCentral

73.

Li D, He Q, Kang T, Yin H, Jin X, Li H, Gan W, Yang C, Hu J, Wu Y, Peng L (2010) Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa/tissue factor from the blood-feeding nematode ancylostoma caninum. Biochem Biophys Res Commun 392(2):155–159. https://doi.org/10.1016/j.bbrc.2009.12.177CrossRefPubMed

74.

Donkor DA, Bhakta V, Eltringham-Smith LJ, Stafford AR, Weitz JI, Sheffield WP (2017) Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep 7(1):2102. https://doi.org/10.1038/s41598-017-02055-xCrossRefPubMedPubMedCentral

75.

Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA (2017) Generation and characterization of aptamers targeting factor XIa. Thromb Res 156:134–141. https://doi.org/10.1016/j.thromres.2017.06.015CrossRefPubMedPubMedCentral

76.

Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372(3):232–240. https://doi.org/10.1056/NEJMoa1405760CrossRefPubMed

77.

Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399(10333):1383–1390. https://doi.org/10.1016/s0140-6736(22)00456-1CrossRefPubMed

78.

Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Diener HC, Gailani D, Kahl A, Donovan M, Perera V, Li D, Hankey GJ (2022) Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 31(10):106742. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106742CrossRefPubMedPubMedCentral

79.

Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH (2022) A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 146(16):1196–1206. https://doi.org/10.1161/circulationaha.122.061612CrossRefPubMed

80.

Salomon O, Zivelin A, Livnat T, Seligsohn U (2006) Inhibitors to factor XI in patients with severe factor XI deficiency. Semin Hematol 43(1 Suppl 1):S10-12. https://doi.org/10.1053/j.seminhematol.2005.11.018CrossRefPubMed

81.

Collins PW, Goldman E, Lilley P, Pasi KJ, Lee CA (1995) Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia 1(4):227–231. https://doi.org/10.1111/j.1365-2516.1995.tb00080.xCrossRefPubMed

82.

George DA, Stuckey DC (2010) Extraction of monoclonal antibodies (IgG1) using anionic and anionic/nonionic reverse micelles. Biotechnol Prog 26(5):1352–1360. https://doi.org/10.1002/btpr.453CrossRefPubMed

83.

Ling G, Kagdi H, Subel B, Chowdary P, Gomez K (2016) Safety and efficacy of factor XI (FXI) concentrate use in patients with FXI deficiency: a single-centre experience of 19 years. Haemophilia 22(3):411–418. https://doi.org/10.1111/hae.12868CrossRefPubMed

84.

Bolton-Maggs P, Goudemand J, Hermans C, Makris M, de Moerloose P (2014) FXI concentrate use and risk of thrombosis. Haemophilia 20(4):e349-351. https://doi.org/10.1111/hae.12457CrossRefPubMed

85.

Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J (2015) Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia 21(4):481–489. https://doi.org/10.1111/hae.12655CrossRefPubMedPubMedCentral

86.

Alsammak MS, Ashrani AA, Winters JL, Pruthi RK (2017) Therapeutic plasma exchange for perioperative management of patients with congenital factor XI deficiency. J Clin Apher 32(6):429–436. https://doi.org/10.1002/jca.21532CrossRefPubMed

87.

Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G (2009) Recommendations for the transfusion of plasma and platelets. Blood Transfus 7(2):132–150. https://doi.org/10.2450/2009.0005-09CrossRefPubMedPubMedCentral

88.

Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R (2011) Clinical review: prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care 15(1):201. https://doi.org/10.1186/cc9311CrossRefPubMedPubMedCentral

89.

Hedner U (2006) Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 124(4):747–757. https://doi.org/10.1016/j.jbiotec.2006.03.042CrossRefPubMed

90.

Hoffman M, Monroe DM 3rd, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9(Suppl 1):S61-65PubMed

91.

Monroe DM (2008) Further understanding of recombinant activated factor VII mode of action. Semin Hematol 45(2 Suppl 1):S7-s11. https://doi.org/10.1053/j.seminhematol.2008.03.013CrossRefPubMed

92.

Duga S, Salomon O (2013) Congenital factor XI deficiency: an update. Semin Thromb Hemost 39(6):621–631. https://doi.org/10.1055/s-0033-1353420CrossRefPubMed

93.

Shapiro AD (2021) Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv 5(1):279. https://doi.org/10.1182/bloodadvances.2019001140CrossRefPubMedPubMedCentral

94.

Knight T, Callaghan MU (2018) The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Hematol 9(10):319–334. https://doi.org/10.1177/2040620718799997CrossRefPubMedPubMedCentral

95.

Barg AA, Budnik I, Avishai E, Brutman-Barazani T, Bashari D, Misgav M, Lubetsky A, Kuperman AA, Livnat T, Kenet G (2021) Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring. Haemophilia 27(3):383–391. https://doi.org/10.1111/hae.14318CrossRefPubMed

96.

Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B (2020) Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost 120(10):1357–1370. https://doi.org/10.1055/s-0040-1714279CrossRefPubMedPubMedCentral

97.

Becker RC (1991) Seminars in thrombosis, thrombolysis and vascular biology. 4. Fibrinolysis. Cardiology 79(3):188–210. https://doi.org/10.1159/000174879CrossRefPubMed

Title: The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease
Authors: Ahmed E. Ali
Richard C. Becker
Publication date: 25-04-2024
Publisher: Springer US
Keywords: Hemophilia
Thrombosis
Anticoagulant
Published in: Journal of Thrombosis and Thrombolysis
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-024-02985-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page